Robert Dee Etherington - 22 Jan 2026 Form 4 Insider Report for Clene Inc. (CLNN)

Reporting relationship: President & CEO, Director
Issuer ticker: CLNN
Reported as of: 22 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2026, 16:12:12 UTC
Prior SEC filing: 30 Sep 2025
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jerome T. Miraglia POA

Key filing fact

Robert Dee Etherington filed Form 4 for Clene Inc. (CLNN) on 23 Jan 2026.

Key facts

This page summarizes Robert Dee Etherington's Form 4 filing for Clene Inc. (CLNN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jan 2026, 16:12.

Change

Previous filing in this sequence was filed on 30 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001835330 Primary reporting owner

Etherington Robert Dee

Relationship: President & CEO, Director
Address: 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Signature: /s/ Jerome T. Miraglia POA
Signature date: 26 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLNN transaction Derivative

stock option

Award

Transaction value: $0
Shares: +75,000
Change %
Price: $0.000000
Shares after: 75,000
Date: 22 Jan 2026
Ownership: Direct
Underlying class: common stock
Underlying amount: 75,000
Exercise price: $5.42
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on January 22, 2026 as an option for 75,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.42 per share. The options vest immediately upon grant.